A Look At Cytokinetics (CYTK) Valuation After Analyst Updates And Myqorzo Launch

Simply Wall St.

Mar 10

Recent analyst updates following Cytokinetics (CYTK) fourth quarter results and the launch of its heart drug Myqorzo have put fresh attention on the stock as investors reassess the company’s long term...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2618670235"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618670235\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618670235?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-10 05:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618670235","market":"hk","top_or_hot":-1,"title":"A Look At Cytokinetics (CYTK) Valuation After Analyst Updates And Myqorzo Launch","media":"Simply Wall St.","content":"<div>\n<p>Recent analyst updates following Cytokinetics (CYTK) fourth quarter results and the launch of its heart drug Myqorzo have put fresh attention on the stock as investors reassess the company’s long term...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/a-look-at-cytokinetics-cytk-valuation-after-analyst-updates\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Cytokinetics (CYTK) Valuation After Analyst Updates And Myqorzo Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Cytokinetics (CYTK) Valuation After Analyst Updates And Myqorzo Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-10 05:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/a-look-at-cytokinetics-cytk-valuation-after-analyst-updates><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recent analyst updates following Cytokinetics (CYTK) fourth quarter results and the launch of its heart drug Myqorzo have put fresh attention on the stock as investors reassess the company’s long term...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/a-look-at-cytokinetics-cytk-valuation-after-analyst-updates\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/a-look-at-cytokinetics-cytk-valuation-after-analyst-updates","article_id":"2618670235","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/a-look-at-cytokinetics-cytk-valuation-after-analyst-updates","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618670235","pubTimestamp":1773091624,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent analyst updates following Cytokinetics (CYTK) fourth quarter results and the launch of its heart drug Myqorzo have put fresh attention on the stock as investors reassess the company’s long term prospects.\nSee our latest analysis for Cytokinetics.\nThose fourth quarter numbers, the Myqorzo launch and the recent shelf registration filing have all come against a backdrop of relatively steady trading, with a 1 day share price return of 3.33% and a much stronger 1 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","CYTK":"Cytokinetics","BK4139":"生物科技"},"translate_title":"分析师更新和Myqorzo推出后Cytokinetics(CYTK)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":1.5},"content_text":"Recent analyst updates following Cytokinetics (CYTK) fourth quarter results and the launch of its heart drug Myqorzo have put fresh attention on the stock as investors reassess the company’s long term prospects. See our latest analysis for Cytokinetics. Those fourth quarter numbers, the Myqorzo launch and the recent shelf registration filing have all come against a backdrop of relatively steady trading, with a 1 day share price return of 3.33% and a much stronger 1 year total shareholder return of 44.12%. This suggests that enthusiasm has been building over time even if near term moves are more muted. If you are looking beyond Cytokinetics and want more ideas in a similar space, this could be a good moment to scan our list of 32 healthcare AI stocks as a fresh source of potential opportunities. With Cytokinetics posting a full year net loss of US$784.96 million yet trading at US$62.42, about 46% below the average analyst target of roughly US$91, investors may ask whether there is still a buying opportunity or whether the market is already pricing in future growth. AdvertisementMost Popular Narrative: 21.5% Undervalued Compared with Cytokinetics’ last close at $62.42, the most followed narrative sets fair value closer to $79.56, framing the recent move as still below that mark.  The fair value estimate has risen slightly to approximately 79.56 dollars from about 78.44 dollars, reflecting modestly higher long term expectations for aficamten. The future P/E multiple has risen meaningfully to around 107.0 times from about 99.5 times, suggesting a higher valuation being placed on projected earnings.  Read the complete narrative. Want to see what justifies paying well above today’s price, yet still calling the stock undervalued? The narrative leans on expectations of rapid revenue compounding, rising margins, and a premium future earnings multiple that is rarely applied to loss making biotechs. Result: Fair Value of $79.56 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on aficamten clearing regulatory hurdles on time and on launch costs not rising so much that they further widen Cytokinetics’ net loss. Find out about the key risks to this Cytokinetics narrative. Next Steps If this mix of optimism and concern feels familiar, it is a good time to look through the numbers yourself and decide where you stand, starting with 2 key rewards and 2 important warning signs. Looking for more investment ideas? If you stop with just one stock, you could miss opportunities that fit your style better, so take a few minutes to scan some focused stock ideas.  Target potential mispricings by reviewing our list of 50 high quality undervalued stocks that pair quality fundamentals with prices the market may be overlooking. Steady your portfolio with income ideas built around 16 dividend fortresses, where yields above 5% come with an emphasis on resilience. Protect against unwanted surprises by filtering for companies in the 66 resilient stocks with low risk scores that score well on balance sheet strength and overall risk.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}